The collaboration with Wyeth has primarily been focused on atherosclerosis but other clinical opportunities have also been explored. The continued collaboration will focus on drug discovery in the field of inflammatory diseases.
Liver X receptor (LXR) is a new member of the nuclear receptor protein family and the receptor plays important roles in cholesterol metabolism and inflammatory responses.
Per Wallstr, president of Karo Bio, said: “Our collaboration with Wyeth has generated numerous compound series and a deepened understanding about LXR function in disease processes. Recently is has been shown that LXR is an important target for treatment of inflammatory disorders and we see exciting opportunities in the continued collaboration.”